Zika virus

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Retrieved on: 
Tuesday, March 26, 2024

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

Key Points: 
  • Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
    the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
  • The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States.
  • Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety profile and immunogenicity in all tested doses and schedules2.
  • This preference stems from the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.

QIAGEN announces partnership with Penn State University to advance microbiome sciences

Retrieved on: 
Thursday, January 25, 2024

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

Key Points: 
  • Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
  • In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center.
  • This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.
  • “Additionally, it will foster relationships with the microbiome research community and enable us to better develop new products for microbiome research based on direct customer feedback.”
    Seth Bordenstein, Director of the One Health Microbiome Center, Professor of Biology and Entomology, and Huck Endowed Chair in the Microbiome Sciences, at Penn State said: “The ‘One Health’ vision shared by QIAGEN and Penn State University is critical for microbiome research.

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Retrieved on: 
Wednesday, January 24, 2024

"Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.

Key Points: 
  • "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
  • We are well-positioned to continue building upon our encouraging growing body of preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
  • With our recent financing in December 2023, we have extended our runway into the fourth quarter of 2024, as well.
  • WP1122 successfully completed a Phase 1 clinical trial, which established a recommended safe dose for future potential Phase 1B or Phase 2 clinical trials.

Global mRNA Platform Market Research Report 2023-2028: Post COVID-19 Vaccines, mRNA's Promise in Cancer Immunotherapy and Personalized Medicine

Retrieved on: 
Friday, December 1, 2023

In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease.

Key Points: 
  • In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease.
  • The Global mRNA Platform Market is poised for remarkable growth, driven by significant advancements, emerging applications, and robust growth drivers.
  • The Global mRNA Platform Market is on an upward trajectory, driven by advancements, emerging applications, and a global response to pandemics.
  • Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.

Key Points: 
  • Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.
  • The global mRNA vaccine market experiences growth driven by the increasing occurrence of cancer, genetic anomalies, and viral infections.
  • This has prompted numerous biotechnology and pharmaceutical companies, along with academic and research institutions, to engage in research, development, and clinical trials for various mRNA vaccines.
  • This, in turn, creates promising prospects for the global mRNA vaccine market during the forecast period.

Fly season: what to know about Australia's most common flies and how to keep them away

Retrieved on: 
Tuesday, October 17, 2023

This year is off to a bumper start, with bush flies swarming beach-goers, March flies on the march, and mosquitoes taking to the skies en masse.

Key Points: 
  • This year is off to a bumper start, with bush flies swarming beach-goers, March flies on the march, and mosquitoes taking to the skies en masse.
  • Despite their sheer diversity, we’re likely to encounter only a select few flies daily.

Familiar faces

    • They slake their thirst on the sweat and tears of mammals and so linger around our heads, shoulders and faces in search of a refreshing drink.
    • These small explorers are otherwise harmless, and pose no serious threat to health or home beyond being a mild nuisance.
    • They are also, however, excellent pollinators, with some orchids relying on their hard work and specialised mouthparts for survival.
    • Malaria is among the farthest-reaching, while Ross River Virus, chikungunya, zika and dengue all circulate with help from mosquitoes.

Shoo fly?


    For the minority of flies that prove a recurring annoyance, the primary goal is to deter rather than kill them. In this case, the remedies are simple:
    • Read more:
      The battle against bugs: it's time to end chemical warfare

      Avoid reaching for the bug-bombs and sprays, which have devastating impacts on beneficial insects.

    • Similarly, those noise-emitting, electrified or smelly gadgets that promise a fly-free existence are best avoided, as most are either ineffective, or harm far more than their intended targets.

From pesky to paramount

    • Flies are among the most diverse animals on the planet, and are utterly crucial for the healthy function of our ecosystems.
    • On the other side of the circle of life are outstanding decomposers, such as black soldier flies.
    • Moreover, flies have proven invaluable in forensics, medicine and scientific research, and environmental monitoring, underscoring how deeply our lives intertwine with theirs.

Fly on

    • The natural world – us included – would not be the same without them.
    • He is also affiliated with the conservation charity Invertebrates Australia.

Experts Warn of Invasive Pests Increasing Their Footprint Across the U.S.

Retrieved on: 
Tuesday, October 10, 2023

“Without natural predators in their environment, invasive pest populations can easily get out of hand,” said Dr. Jim Fredericks, Senior Vice President of Public Affairs at NPMA.

Key Points: 
  • “Without natural predators in their environment, invasive pest populations can easily get out of hand,” said Dr. Jim Fredericks, Senior Vice President of Public Affairs at NPMA.
  • “If you suspect an invasive pest infestation in or around your home immediately contact a pest control professional.
  • According to a new survey from NPMA conducted online by The Harris Poll, nearly 1 in 5 (18%) Americans have found invasive pests in their home and 17% are concerned about the threats posed by invasive species.
  • To learn more about invasive pests and the threats they pose, visit PestWorld.org .

Nobel prize in medicine awarded to mRNA pioneers – here's how their discovery was integral to COVID vaccine development

Retrieved on: 
Monday, October 2, 2023

The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus.

Key Points: 
  • The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus.
  • Their discovery was not only integral to COVID-19 vaccine development, but may also lead to the development of many other therapies – such as vaccines for cancer.

Life’s work

    • It’s made in the body from our very own DNA in a process called translation.
    • DNA is our special encoded handbook of instructions for manufacturing proteins, which are the building blocks for material in the body.
    • The cells then make whatever protein they’ve been instructed to, such as haemoglobin for helping red blood cells carry oxygen around the body.
    • The researchers faced two major challenges as they began their work.
    • Karikó and Weissman’s research had successfully eliminated the obstacles that had previously stood in the way of using mRNA clinically.

COVID vaccines

    • Researchers had already been working on developing mRNA vaccines before the pandemic, such as a vaccine for Ebola that didn’t receive much commercial interest.
    • This produced a harmless COVID particle which our cells then replicated, allowing our bodies to protect us from severe COVID infections when it encountered the real virus.
    • Studies have also shown mRNA vaccines might be useful in treating certain types of cancer.

All of Beer Announces MosquitoniX Chemical-Free Mosquito Repellent Wrist Band

Retrieved on: 
Tuesday, July 4, 2023

Oberiberg, Switzerland--(Newsfile Corp. - July 3, 2023) - All of Beer has announced the MosquitoniX Band, a battery-powered wearable band that can repel mosquitoes.

Key Points: 
  • Oberiberg, Switzerland--(Newsfile Corp. - July 3, 2023) - All of Beer has announced the MosquitoniX Band, a battery-powered wearable band that can repel mosquitoes.
  • Available in minimalistic designs, the MosquitoniX Band can be worn on the wrist as the user carries out their daily activities.
  • For consumers looking for chemical-free alternatives, All of Beer recommends the MosquitoniX Band as a non-toxic and non-intrusive mosquito repellent.
  • The MosquitoniX Band also sets itself apart from other wearable repellents by having three distinct settings.